BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gómez-Junyent J, Benavent E, Sierra Y, El Haj C, Soldevila L, Torrejón B, Rigo-Bonnin R, Tubau F, Ariza J, Murillo O. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Int J Antimicrob Agents 2019;53:612-9. [PMID: 30682497 DOI: 10.1016/j.ijantimicag.2019.01.010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Horcajada JP, Montero M, Oliver A, Sorlí L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev 2019;32:e00031-19. [PMID: 31462403 DOI: 10.1128/CMR.00031-19] [Cited by in Crossref: 232] [Cited by in F6Publishing: 148] [Article Influence: 77.3] [Reference Citation Analysis]
2 Martin I, Waters V, Grasemann H. Approaches to Targeting Bacterial Biofilms in Cystic Fibrosis Airways. Int J Mol Sci 2021;22:2155. [PMID: 33671516 DOI: 10.3390/ijms22042155] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
3 Montero M, Domene Ochoa S, López-Causapé C, VanScoy B, Luque S, Sorlí L, Campillo N, Angulo-Brunet A, Padilla E, Prim N, Pomar V, Rivera A, Grau S, Ambrose PG, Oliver A, Horcajada JP. Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model. Antimicrob Agents Chemother 2020;64:e02542-19. [PMID: 32041712 DOI: 10.1128/AAC.02542-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Yu S, Pu X, Ahmed MU, Yu HH, Mutukuri TT, Li J, Zhou QT. Spray-freeze-dried inhalable composite microparticles containing nanoparticles of combinational drugs for potential treatment of lung infections caused by Pseudomonas aeruginosa. Int J Pharm 2021;610:121160. [PMID: 34624446 DOI: 10.1016/j.ijpharm.2021.121160] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ribera A, Benavent E, El-Haj C, Gomez-Junyent J, Tubau F, Rigo-Bonnin R, Ariza J, Murillo O. Comparative Antibiofilm Efficacy of Meropenem Alone and in Combination with Colistin in an In Vitro Pharmacodynamic Model by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2019;63:e01230-19. [PMID: 31481437 DOI: 10.1128/AAC.01230-19] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Malik MS, Ahmed SA, Althagafi II, Ansari MA, Kamal A. Application of triazoles as bioisosteres and linkers in the development of microtubule targeting agents. RSC Med Chem 2020;11:327-48. [PMID: 33479639 DOI: 10.1039/c9md00458k] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 7.5] [Reference Citation Analysis]
7 Ronda M, Pérez-Recio S, González Laguna M, Tubau Quintano MF, Llop Talaveron J, Soldevila-Boixader L, Carratalà J, Cuervo G, Padullés A. Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience. J Clin Pharm Ther 2022. [PMID: 35255527 DOI: 10.1111/jcpt.13623] [Reference Citation Analysis]
8 Soares A, Alexandre K, Etienne M. Tolerance and Persistence of Pseudomonas aeruginosa in Biofilms Exposed to Antibiotics: Molecular Mechanisms, Antibiotic Strategies and Therapeutic Perspectives. Front Microbiol 2020;11:2057. [PMID: 32973737 DOI: 10.3389/fmicb.2020.02057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Montero MM, Domene Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, López Montesinos I, Padilla E, Prim N, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Microbiol Spectr 2021;9:e0058521. [PMID: 34319141 DOI: 10.1128/Spectrum.00585-21] [Reference Citation Analysis]
10 Gómez-Junyent J, Murillo O, Yu HH, Azad MAK, Wickremasinghe H, Rigo-Bonnin R, Benavent E, Ariza J, Li J. In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion alone and in combination with colistin against Pseudomonas aeruginosa biofilm. Int J Antimicrob Agents 2021;57:106246. [PMID: 33253904 DOI: 10.1016/j.ijantimicag.2020.106246] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Li L, Wang Q, Gao Y, Liu L, Duan Y, Mao D, Luo Y. Colistin and amoxicillin combinatorial exposure alters the human intestinal microbiota and antibiotic resistome in the simulated human intestinal microbiota. Science of The Total Environment 2021;750:141415. [DOI: 10.1016/j.scitotenv.2020.141415] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
12 Adembri C, Cappellini I, Novelli A. The role of PK/PD-based strategies to preserve new molecules against multi-drug resistant gram-negative strains. J Chemother 2020;32:219-25. [PMID: 32628094 DOI: 10.1080/1120009X.2020.1786634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Karmakar PD, Pal S. Dextran based amphiphilic self-assembled biopolymeric macromolecule synthesized via RAFT polymerization as indomethacin carrier. Int J Biol Macromol 2021;183:718-26. [PMID: 33930447 DOI: 10.1016/j.ijbiomac.2021.04.145] [Reference Citation Analysis]
14 Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 2022;11:579. [DOI: 10.3390/antibiotics11050579] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Ho S, Nguyen L, Trinh T, MacDougall C. Recognizing and Overcoming Resistance to New Beta-Lactam/Beta-Lactamase Inhibitor Combinations. Curr Infect Dis Rep 2019;21:39. [PMID: 31501948 DOI: 10.1007/s11908-019-0690-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
16 Bilal H, Bergen PJ, Kim TH, Chung SE, Peleg AY, Oliver A, Nation RL, Landersdorfer CB. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Antimicrob Agents Chemother 2019;63:e01293-19. [PMID: 31427301 DOI: 10.1128/AAC.01293-19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]